Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Metastatic CRC: Nivolumab Plus Regorafenib

August 17th 2021

Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.

Early Screening for Colorectal Neoplasia and Cancer Is Critical Among Younger Individuals

August 11th 2021

Steven H. Itzkowitz, MD, discusses the importance of screening for CRC in younger adults, the results of the database analysis, and strategies for implementing early messaging in the community setting for this population.

Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions

August 10th 2021

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.

MSI-H Metastatic CRC: Chemo Vs I-O Debated

August 10th 2021

Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.

Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

August 10th 2021

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

MSI-H Metastatic CRC: Frontline Immunotherapy

August 10th 2021

Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.

Dr. Cohen on the Standardization of Triplet Chemotherapy in CRC

August 4th 2021

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.

Metastatic CRC: Frontline Therapy With EGFR Inhibitors

August 3rd 2021

Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.

MSS Metastatic CRC: First-Line Treatment Selection

August 3rd 2021

Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.

Triplet Combination Demonstrates Promise for Frontline Treatment of BRAF V600E–mutant CRC

July 28th 2021

Doublet and triplet chemotherapy-based therapies are standard treatment options for patients with BRAF V600–mutant metastatic colorectal cancer.

Anti-EGFR/Chemo Combos Allow for Tailored Approach in mCRC

July 28th 2021

Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing indications.

Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC

July 27th 2021

Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.

Molecular Markers and Tumor Sidedness in Metastatic CRC

July 27th 2021

Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.

Treatment Gaps for Patients With Metastatic CRC

July 27th 2021

Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.

Dr. Cohen on the Preliminary Results of the GALAXY Study in CRC

July 21st 2021

Stacey A. Cohen MD, discusses the preliminary results of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Dr. Jones on Targeting HER2 Alterations in CRC

July 20th 2021

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC

July 15th 2021

Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Genomics, Sidedness Guide Treatment Selection in Metastatic CRC

July 14th 2021

Zev A. Wainberg, MD, and Jaffer A. Ajani, MD, discuss how to best utilize information provided to inform treatment decisions, treatment approaches for patients with newly diagnosed RAS wild-type mCRC, and factors that affect influence selecting a 2- vs 3-drug chemotherapy regimen.

Regorafenib/Nivolumab Elicits Better Responses in pMMR/MSS CRC Without Liver Metastases

July 14th 2021

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Dr. Jones on the Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in CRC

July 12th 2021

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.